Cloning of Variable Domains from Mouse Hybridoma by PCR

  • Nina Strebe
  • Frank Breitling
  • Dieter Moosmayer
  • Bodo Brocks
  • Stefan DübelEmail author
Part of the Springer Protocols Handbooks book series (SPH)

Some hybridoma cell lines are very low producers, difficult to cultivate, or antibody production is lost upon prolonged culture. In these cases, a recombinant "hybridoma immortalization" can rescue a valuable antibody for further unlimited propagation in E. coli or other recombinant production systems. Further, monoclonal antibodies with promising specificity, but low affinity, can be improved by phage display, or mouse antibodies can be humanised for therapy. This chapter describes sets of thoroughly validated oligonucleotide primers for a PCR procedure to isolate and clone the DNA of antibody Fv fragments (antigen binding region) from mouse and rat hybridoma cell lines. The protocol includes a colony staining assay to identify E. coli clones producing scFv antibody fragments.


Polymerase Chain Reaction Polymerase Chain Reaction Product Phage Display Library Hybridization Temperature scFv Fragment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Breitling F, Dübel S (1999) Recombinant antibodies. Wiley, New York, ISBN:0-471-17847-0Google Scholar
  2. Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D (2001) Species-crossreactive scFv against the tumor stroma marker “fibroblast activation protein” selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med 7:461–469PubMedGoogle Scholar
  3. Dübel S, Breitling F, Klewinghaus I, Little M (1992) Regulated secretion and purification of recombinant antibodies in E.coli. Cell Biophys 21:69–79PubMedGoogle Scholar
  4. Dübel S, Breitling F, Fuchs P, Zewe M, Gotter S, Moldenhauer G, Little M (1994) Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods 175:89–95PubMedCrossRefGoogle Scholar
  5. Evan GI, Lewis GK, Ramsay G, Bishop M (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610–3616PubMedGoogle Scholar
  6. Fuchs P, Breitling F, Little M, Dübel S (1997) Primary structure and functional scFv antibody expression of an antibody against the human protooncogen c-myc. Hybridoma 16:227–233PubMedCrossRefGoogle Scholar
  7. Liu Z, Song D, Kramer A, Martin AC, Dandekar T, Schneider-Mergener J, Bautz EK, Dübel S (1999) Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from Drosophila melanogaster. J Mol Recognit 12:103–111PubMedCrossRefGoogle Scholar
  8. Moosmayer D, Dübel S, Brocke B, Watzka H, Hampp C, Scheurich P, Little M, Pfizenmaier K (1995) A single chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Ther Immunol 2:31–40PubMedGoogle Scholar
  9. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning. A laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NYGoogle Scholar
  10. Schiweck W, Buxbaum B, Schatzlein C, Neiss HG, Skerra A (1997) Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: the V(H) domain has an extended CDR-H3 and exhibits unusual solubility. FEBS Lett 414:33–38PubMedCrossRefGoogle Scholar
  11. Strebe N, Guse A, Schüngel M, Schirrmann T, Hafner M, Jostock T, Hust M, Müller W, Dübel S (2009) Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. J Immunol Methods 341:30–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Nina Strebe
    • 1
    • 2
  • Frank Breitling
    • 3
  • Dieter Moosmayer
    • 4
  • Bodo Brocks
    • 5
  • Stefan Dübel
    • 6
    Email author
  1. 1.Institut für Biochemie und BiotechnologieTechnische Universität BraunschweigBraunschweigGermany
  2. 2.Sanofi-Aventis Deutschland GmbHFrankfurt am MainGermany
  3. 3.Karlsruhe Institute of Technology76344 Eggenstein-LeopoldshafenGermany
  4. 4.Bayer Schering Pharma AGBerlinGermany
  5. 5.Bodo Brocks, MorphoSys AGMartinsriedGermany
  6. 6.Institut für Biochemie und BiotechnologieTechnische Universität BraunschweigBraunschweigGermany

Personalised recommendations